SYFf9c36b22e9754f51968fa19506e99f36

UnknownPhase 1

A study to investigate the similarity of two different Tiotr...

CCDRD Cooperative Clinical Drug Research and Development AG Source

Compare

Study Type

interventional

Reported enrollment (type unavailable)

N/A

Locations

1 country

Sites

2

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: unknown
Reported enrollment (type unavailable): Not reported
Study completion date: Not reported
Date not reported
Listed locations: 1 countries · 2 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

First Submitted
July 3, 2024
Actual (reported)

Conditions

No therapeutic indication in the current trial with healthy volunteers.

Sponsors & Collaborators

CCDRD Cooperative Clinical Drug Research and Development AG
Industrylead
Invox Belgium
Industryco_sponsor

Study Sites (2)

Diagnostic Consultative Centre Ascendent EOOD

Sofia, 1202, Bulgaria

Ivo Bogdanov+35929839494 ivoatbog@gmail.com

Clinic of Clinical Pharmacology and Therapeutics UMHAT 'Tsaritsa Ioanna-ISUL' EAD

Sofia, 1527, Bulgaria

Emil Gatchev+35929432152 clinpharm.isul@gmail.com

Central Study Contacts

Head of Regulatory

+3211286994 marie.morris@invoxpharma.com

Head of Regulatory

+32471761005

Study Design

Study Type: interventional
Phase: phase 1

Study Record Dates

First Submitted

July 3, 2024

Source record

Download the complete CTIS (EMA) record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: European Medicines Agency (EMA), Clinical Trials Information System (CTIS). Original record and public documents are available on CTIS.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: 2023-509025-41-00
Data provider: European Medicines Agency (EMA)
Normalization version: ctis-v1

Open registry record

Source retrieved: 2026-10-29 06:23:28 UTC

Locations

BG(2)

SYF18720e83653e4c419f10d58646cac84c

Evaluation of the bioequivalence of two products containing esomeprazole under fed conditions: Esomeprazole-Syrup 40 mg dose (Test) vs. Nexium 40 mg (Comparator). An open, randomized, single dose, four-period, replicate, crossover trial in healthy volunteers

Phase 1Unknown

SYFb3b818a7a6ea4efa84f41d5e26a7cd29

Evaluation of the bioavailability of two products containing esomeprazole under fasting and fed conditions: Esomeprazole-Syrup 40 mg dose (Test) vs. Nexium 40 mg (Comparator). A monocentric, open, randomized, single dose, four-period, crossover trial in healthy volunteers

Phase 1Unknown

SYFce2256bb647d434da75c12fe9d8f48b2

Evaluation of bioequivalence of two products containing 600 mg ibuprofen: Ibuprofen Sopharma 600 mg film-coated tablets (Test) vs. Brufen 600 mg film-coated tablets (Comparator). A monocentric, open, randomized, single dose, two-period, crossover trial in healthy volunteers

Phase 1Unknown

SYF6ed0f8284d8b4f8889b4688057dd752f

Evaluation of bioequivalence of two products containing 400 mg ibuprofen and 100 mg caffeine: Ibuprofen / Caffeine 400 mg / 100 mg coated granules (Test) vs. Thomapyrin TENSION DUO, 400mg / 100mg Filmtabletten (Reference). A monocentric, open, randomized, single dose, two-period, crossover trial in healthy volunteers

Phase 1Unknown

SYF044ec59472d94215ac47522e57e4355f

Evaluation of the bioavailability of two transdermal gel preparations containing 0.1% w/w estradiol under fasting conditions: Estradiol/INTERMED gel 0.1% w/w (Test) vs. ESTREVA® 0.1%, gel (Comparator). A monocentric, open, randomized, single dose, two-period, crossover trial in healthy postmenopausal women

Phase 1Unknown

SYFd5b65c77d98d40beb5639ad669fb7568

Evaluation of bioequivalence of two products containing estradiol: Estradiol/INTERMED gel 0.1% w/w (Test) vs. ESTREVA 0.1% gel (Comparator). An open, randomized, single-dose, four-period, full-replicative trial in healthy postmenopausal women

Phase 1Recruiting

SYF124052c7b7e146aa9b8a24b0f3e5e8e3

Evaluation of the bioequivalence of two intravaginal gel preparations containing 90 mg progesterone

Phase 1Not Yet Recruiting

marie.morris@invoxpharma.com